Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer

Stopped early · Phase 1

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving stereotactic body radiation therapy together with gemcitabine hydrochloride may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of stereotactic body radiation therapy when given with or without gemcitabine hydrochloride in treating patients with pancreatic cancer that can be removed by surgery.

Key facts

Study ID
NCT01025882
Run by
University of Texas Southwestern Medical Center
People needed
5
Starts
2009-10-01
Expected to finish
2011-02-18
Last updated by the study team
2019-02-05

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.